Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A Korean partnership
May 2018
SHARING OPTIONS:

BOSTON—PAREXEL International Corp. and CHA Medical Group have launched an alliance to boost early-phase clinical development in Korea, specifically to offer comprehensive services combining PAREXEL’s global clinical research and regulatory knowhow with CHA’s experience with conducting early-phase studies in Korea.
 
“Enrollment challenges are a primary cause of delays in Phase 1/2 studies which involve target patient populations, and many companies struggle with gaining access to patients while conducting trials in a safe and controlled environment,” said Stanford Jhee, corporate vice president of early-phase scientific affairs at PAREXEL. “With this partnership, we are aiming to bring our biopharmaceutical clients interested in conducting trials in Korea not only broad access to patients, but the expertise necessary to conduct the trials from start to finish, generate quality Phase 1 data needed for global development and gain the market advantage essential to commercial success.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.